Advanced Search

 

Study ID Status Title Patient Level Data
SLGA5021 Completed A randomized, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg b.i.d.* plus fluticasone propionate 88mcg b.i.d.* versus fluticasone propionate 220mcg b.i.d.* alone in subjects with asthma not well controlled on fluticasone propionate 88mcg b.i.d.*
SLGA5022 Completed A randomised, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg b.i.d.* plus fluticasone propionate 88mcg b.i.d.* versus fluticasone propionate 220mcg b.i.d.* alone in subjects with asthma not well controlled on fluticasone propionate 88mcg b.i.d.*
SLGA5024 Completed A randomized, double-blind, parallel group, comparison of inhaled salmeterol xinafoate (42mcg BID) with oral zafirlukast (20mg BID) in subjects with mild to moderate asthma.
SLGA5025 Completed A randomized, double-blind, parallel group, comparison of inhaled salmeterol xinafoate (42mcg BID) with oral zafirlukast (20mg BID) in subjects with mild to moderate asthma.
SLGB1002 Completed A study to investigate to what extent the swallowed fraction of an inhaled dose of salmeterol contributes to its systemic effects.
SLGB1005 Completed A study to investigate the potential interaction between terfenadine, erythromycin and salmeterol.
SLGB1006 Completed A Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Compare the Systemic Pharmacodynamic Effects and Pharmacokinetics of Salmeterol Delivered by the Non-CFC Propellant (HFA-134a; GR106642X) and the CFCPropellant (Propellant 11/12) Metered Dose Inhalers in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
SLGB3019 Completed A multicentre, randomised, double-blind, parallel group study comparing the efficacy and safety of inhaled salmeterol xinafoate 50mcg bd with that of salbutamol 200mcg to use as required from Diskhalers for twelve months in children with asthma.
SLGB4003 Completed A double-blind randomised, placebo controlled, crossover study to evaluate the duration of protection from exercise induced bronchospasm of inhaled salmeterol xinafoate 50µg (from a Diskhaler) after a single dose and after treatment with 50µg twice daily, for 28 days in children and adolescents ...
SLGB4007 Completed A comparison of salmeterol via Diskhaler with salmeterol via multi-dose powder inhaler in children with exercise-induced asthma.
SLGB4010 Completed A multi-centre double-blind, parallel group study to evaluate the relative clinical benefits of three treatment interventions: i) salmeterol xinafoate 50 mcg bd plus fluticasone propionate 250 mcg bd; ii) fluticasone propionate 500 mcg bd; iii) fluticasone propionate 250 mcg bd, in adult asthmat ...
SLGB4011 Completed A phase IV, multi-centre, randomised, double-blind, placebo-controlled, crossover study to assess the effect of salmeterol xinafoate (Severent) 50 micrograms bd on nocturnal awakenings and sleep dynamics when added to existing therapy in children with nocturnal symptoms of asthma.
SLGB4014 Completed Placebo controlled study during one year comparing the addition of salmeterol with an increase of the dose of the inhaled corticosteroid in asthmatic children already on treatment with inhaled corticosteroids.
SLGB4015 Completed One year treatment with either inhaled corticosteroid or a long acting beta-2-agonist in asthmatic children.
SLGF53 Completed A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
SLGF55 Completed Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Extensive searching has revealed that no clinical study report is available for this study.
SLGF75 Completed (Inhaled Fluticasone propionate and Salmeterol in sputum induced study in asthma)Salmeterol plus low-dose fluticasone propionate (FP) versus high-dose fluticasone propionate (FP) in naive patients with mild to moderate asthma: effects on pulmonary function, and inflammatory markers of induced sputum
SLGH01 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses (50mcg, 100mcg, and 200mcg) of GR33343G in Patients With Reversible Airways Obstruction
SLGH03 Completed The Determination of the Relative Potency of Inhaled GR33343G Metered-Dose Inhaler and GR33343G Dry Powder: A Cumulative Dose-Response Study in Patients With Reversible Airways Disease
SLGH04 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses (12.5mcg, 25mcg, 50mcg, and 100mcg) of GR33343G in Patients With Asthma. A Randomised, Double-Blind Comparison With Inhaled Salbutamol.
SLGH05 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses of GR33343G (12.5mcg, 25mcg, 50mcg, and 100mcg) Administered as a Dry Powder. A Comparison With Salbutamol (200mcg) Administered From a Metered-Dose Inhaler.
SLGH06 Completed A Single-Centre, Double-Blind, Within-Patient Study to Determine the Dose-Response Characteristics of GR33343G (12.5mcg-100mcg) Given by Metered-Dose Inhaler in Patients With Asthma. A Comparison With Salbutamol (200mcg) Given by Metered-Dose Inhaler.
SLGH07 Completed To Determine the Dose-Response Characteristics of Inhaled Dry Powder GR33343G 12.5mcg, 25mcg, 50mcg, and 100mcg in Patients With Asthma: A Comparison With Inhaled Salbutamol 200mcg
SLGH08 Completed A Single-Centre, Single-Dose, Double-Blind, Cross-Over Study to Compare the Bronchodilator Effects of 50mcg GR33343G Metered-Dose Inhaler and 50mcg GR33343G Dry Powder in Asthmatic Patients
SLGH10 Completed A Double-Blind Cross-Over Study to Determine if 50mcg Inhaled GR33343G (salmeterol) Twice Daily Compared With Salbutamol for 13 Days Caused Tachyphylaxis in Patients With Stable Asthma

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.